Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.37 Analyst target: $12.62 Upside: 274.48%
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.